The placebo response remains one of the most significant challenges in Crohn’s disease and ulcerative colitis drug development. High placebo response rates of 20-33% are eroding the efficacy margins that impact regulatory and development decisions, determining whether your program succeeds or fails.
Factors including disease severity, endpoint selection, patient populations, study conduct, and operational execution can all influence placebo rates and impact the ability of clinical trials to detect treatment effects. But what if the placebo response is not simply an unavoidable feature of IBD clinical research?
This white paper gives you the tools to identify the patient selection, endpoint, and operational drivers of placebo response rates in your Crohn’s disease and ulcerative colitis clinical trials, and a practical framework to reduce placebo susceptibility and improve signal detection and study success from protocol design through study execution.
Get the white paper.
Talk to a PSI expert.
Select what’s most useful for your program – the white paper, a direct conversation, or both.
* indicates required fields
Practical placebo response reduction framework
Patient selection and baseline characteristics:
Mandatory inflammation confirmation
It is important to select patients whose disease biology limits spontaneous improvement. All enrolled patients should demonstrate inflammation across at least two independent objective parameters. no single biomarker is sufficiently reliable, due to, for example, CRP non-responders, reduced fecal calprotectin sensitivity in ileal CD, and disease heterogeneity.
Recommended enrollment criteria
| Parameter | Recommended threshold |
|---|---|
| UC endoscopy | MES >2 |
| CD endoscopy | SES-CD >6, >4 for patients with isolated ileal diseasea |
| UC fecal calprotectin | >500 ɥg/g |
| UC fecal calprotectin (colonic, less reliable in ileal) | >300 ɥg/g |
| CRP | Use as stratification and not sole inclusion |
| Albumin | Record and stratify |
| Disease duration | Stratify in CD |
